In the non-cardiac setting, MV and TLG have shown reliable correlations with serologic markers of tumor burden (e.g. LDH and S-100 protein) and inflammation (e.g. CRP).5,9 Moreover, changes of MV and TLG during oncological therapy correlate with treatment response and clinical outcome in a variety of tumor entities.4,10–14 However, very little is known with respect to the performance of these quantitative 18F-FDG PET/CT-derived parameters in the setting of infection, particularly in IE. Here, CRP is linked to neoplasm.